Shares of Verici Dx plc (LON:VRCI – Get Rating) traded down 3% during mid-day trading on Thursday . The stock traded as low as GBX 16 ($0.19) and last traded at GBX 16 ($0.19). 14,777 shares changed hands during trading, a decline of 89% from the average session volume of 138,717 shares. The stock had previously closed at GBX 16.50 ($0.20).
Verici Dx Stock Performance
The company has a debt-to-equity ratio of 2,309.09, a current ratio of 8.66 and a quick ratio of 8.49. The company’s 50-day moving average price is GBX 19.99 and its two-hundred day moving average price is GBX 24.66. The company has a market capitalization of £27.25 million and a price-to-earnings ratio of -3.33.
About Verici Dx
Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure.
- What Steelcase’s Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.